“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...

Pulling the Pfizer EUA would remove the only COVID-19 vaccine approved for all children from the US market. The Moderna ...

The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

Novavax COVID vaccine shows strong efficacy The biotechnology company announced Monday that its stage three clinical trial showed overall efficacy of 90.4% against COVID-19.

The federal government’s move to pull hundreds of millions of dollars in funding for mRNA vaccines could be a shot in the arm ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda , sending its ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

A Food and Drug Administration official who stepped down less than two weeks ago is getting his job back as the agency’s top ...

The company announced the vaccine's efficacy was 91% in "high-risk" populations. Novavax researchers also took a close look at sequencing data for 54 of the 77 Covid-19 cases in the study.